Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asahi Kasei Pharma To Expand Naftopidil Market Share

This article was originally published in PharmAsia News

Executive Summary

Asahi Kasei Pharma will expand market share for benign prostate hyperplasia drug Flivas (naftopidil) in Japan. The company obtained the drug's intellectual property rights from Roche Diagnostics. Asahi Kasei sees a stronger demand for the drug since the sales of competeing drugAvishot (naftlopidil), manufactured by Organon Japan (now Schering Plough) will be halted by Schering Plough by March 2010. Asahi also plans to increase medical representatives by 50 percent to 900 by 2014 and double sales from ¥50 billion to ¥100 billions by 2015. To speed new drug development, the company aims to increase research and development investment by ¥2 billion each year for 2009 and 2010, and reach ¥14 billion in 2010. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069872

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel